mercredi 6 juin 2018

Onco Actu du 6 juin 2018

5.12 Immunothérapies

A Promising Cancer Treatment Made Patients Worse, Not Better [NY Times]

5.12.8 Immunothérapies - Economie

Life-extending lung cancer drug will be more widely available on the NHS after NICE review [NICE]

NICE recommends MSD's Keytruda for advanced PD-L1-positive lung cancer [Pharmafile]

5.2 Pharma

Zai Lab grabs top AstraZeneca cancer executive to prep its first drug rollout [FiercePharma]

5.4 Traitements - Economie

NICE rules against first-line use of Ipsen’s Cabometyx [PharmaTimes]

5.5.1 ASCO (général)

ASCO Highlights for Tuesday June 5, 2018 [OBR Blog]

Doctors Scrutinize Overtreatment, As Cancer Death Rates Decline [NPR]

ASCO 2018 conference round up [ecancertv]

ASCO Wrap: Cancer Combos, Precision Meds, Stock Movers & More [Xconomy]

5.5.10 ASCO (hémato)

Toxin-Based Drug Moxetumomab Pasudotox May Be New Option for Rare Leukemia [NCI]

5.5.13 ASCO (divers)

A hyped news release gets revised at ASCO: Did it lead to improved coverage from journalists? [HealthNewsReview]

5.5.16 ASCO (médecine de précision)

WIN Consortium Applies Transcriptomics to Bolster Patient Matching in Precision Oncology Study [Genome Web]

Personalised medicine 'transforms' survival chances in incurable cancer [The Telegraph]

Tailoring cancer treatment to genetic profile extends lives, study finds [The Guardian] ASCO (médecine de précision-sein)

Genomic Health Stock Soars After TAILORx Data Clarifies Utility of Oncotype DX [Genome Web]

Take that, Mike Adams! The TAILORx study vs. the alt-med stereotype of oncologists anxious to administer toxic chemotherapy [Respectful Insolence]

5.5.3 ASCO (prostate)

ASCO: AstraZeneca pioneer Lynparza scores with Zytiga combo in prostate cancer [FiercePharma] ASCO (immunothérapies-CAR-T, thérapies cellulaires)

More Thoughts on AbbVie’s Rova-T Implosion [In the Pipeline]

#ASCO18: AbbVie convinces one top analyst that its $6B ‘megablockbuster’ Rova-T is worthless [EndPoints]

5.5.5 ASCO (gastro-intestinal)

New Treatment Combination Improves Outcomes for Some Patients with Colorectal Cancer [Roswell Park]

6. Lutte contre les cancers

Europe’s top science funder shows high-risk research pays off [Nature]

6.1 Observation

Prostate cancer survival odds worse for smokers [Reuters]

6.10.1 Politiques (USA)

The ‘cruel joke’ of compassionate use and right to try: Pharma companies don’t have to comply [STAT]

6.7 DMP, Big Data & applis

Companies to Help People Sell or Rent Out Their Health Data [The Scientist]

6.7.1 IA/bioinformatique

Inside Amazon's Grand Challenge — a secretive lab working on cancer research and other ventures [CNBC]